ACT-1

ACT-1 is a peptide mimetic derived from the carboxyl terminus of connexin 43, the most widespread gap junction protein in the body, and it is rendered cell-permeant so that it can enter cells and reach its intracellular target ^[1][3]. The peptide carries a PDZ-binding sequence that lets it interfere with the interaction between Cx43 and the tight-junction scaffolding protein zonula occludens-1 (ZO-1) ^[2][4]. It was developed by Robert Gourdie and colleagues and has been advanced commercially under names including αCT1 and aCT1 ^[3][5].

Across preclinical models the peptide has consistently shifted healing away from scarring and toward more regenerative repair. Applied to skin wounds it reduced inflammation, shrank the area of scar-forming tissue, and improved the structure and mechanical strength of healed skin ^[3]. In the heart, local delivery after ventricular injury preserved Cx43 at the intercalated discs, reduced gap-junction remodeling, and lowered the likelihood of inducible arrhythmia ^[2]. It also modulated the fibrous encapsulation response to silicone implants, improving their integration ^[1], and, delivered as eye drops, stabilized retinal pigment epithelium junctions in models of age-related macular degeneration ^[4].

ACT-1 progressed from laboratory studies into clinical development, with formulations tested for skin wounds and scar reduction and a Phase III program reported for the treatment of diabetic foot ulcers ^[5]. Reviews describe connexin-based therapeutics such as this peptide as a promising way to beneficially adjust the body's natural healing response ^[5]. It is an investigational compound rather than an established, widely approved medicine, and it is not a dietary supplement ^[5].

ACT-1 (alpha-CT1) is a connexin-43 carboxyl-terminal mimetic peptide investigated mainly in preclinical and early wound-healing and tissue-repair research; human safety data are limited and it is sold as a research chemical. Because it modulates gap-junction and hemichannel signaling involved in cardiac, wound and tissue function, its systemic effects, immunogenicity and long-term safety in humans are poorly characterized and should not be assumed benign.

ACT-1, more properly written alphaCT1, emerged from the laboratory of Robert G. Gourdie and colleagues, who reasoned that a short peptide copying the extreme carboxyl terminus of connexin 43 could competitively occupy the binding site normally used by the tight-junction scaffold ZO-1. Fused to a cell-penetrating antennapedia sequence so it could cross the cell membrane, the peptide was first characterized in the mid-2000s as a tool for manipulating gap-junction organization. It was subsequently developed as an investigational therapeutic by FirstString Research and advanced into human testing as a topical gel formulation. Phase I and Phase II clinical trials examined its use for surgical scar reduction and chronic wounds such as diabetic foot ulcers and venous leg ulcers, with one Phase II study reporting an improvement in scar appearance of roughly 47% at nine months after surgery.

Within regenerative-medicine and connexin research, alphaCT1 is regarded as one of the more compelling examples of a rationally designed peptide that reached genuine clinical evaluation rather than remaining a bench curiosity. Investigators have been drawn to the observation that treated wounds tend to lay down collagen in a less rigidly aligned pattern that more closely resembles uninjured skin, a structural signature linked to better long-term scar quality. Its dual relevance to both cutaneous scarring and cardiac injury has broadened interest across dermatology and cardiology. That said, the evidence base remains early stage; results come from a limited number of trials and animal models, and alphaCT1 is best understood as a promising experimental agent whose full clinical value is still being established.